279 CERAMIDE-NP IN SKIN-SIMULATING LIPOSOME FORMULATIONS
liposome formulation were given in Figure 2. The liposomes were centrifuged for 30
minutes at 3,000 rpm and parted from the dispersion medium. Then, the liposome was
dissolved in a mixture of methanol and tetrahydrofuran (1:1, v/v). Cer-NP was quantified
with a suitable dilution of sample solutions by HPLC.
Preparation of standard solutions. The Cer-NP is poorly soluble in hydrophilic or aqueous
solutions because of its high lipophilicity.15 Therefore, the stock solutions of Cer-NP were
prepared by dissolving the lipids in methanol/tetrahydrofuran (1:1) at 480 µg/mL. The
standard solutions were performed by suitable dilution of stock solutions in methanol/
tetrahydrofuran at various concentrations (80, 200, 320, 400, and 480 µg/mL).
ANALYTICAL EQUIPMENT AND CHROMATOGRAPHIC
The lipid solution sample was analyzed at an HPLC-equipped DAD-detector (LC-20AD
Model, Shimadzu, Kyoto, Japan) in a range of 190 nm and 800 nm wavelength, to choose an
appropriate wavelength for the next analysis. The reversed-phase C-18 (150 mm × 4.6 mm,
5 µm) column (Macherey-Nagel, Dueren, Germany) was used as a stationary phase. The
mobile phase ingredients were chosen as methanol (P’ =3.0) and acetonitrile (P’ =3.1)
based on their reversed phase polarity.12 The different chromatographic conditions include
various compositions of mobile phase (from 100% to 60% of methanol in acetonitrile),
flow rate (0.5 mL/min, 0.8 mL/min, and 1.0 mL/min), and injection volume (10 µL, 50 µL,
and 80 µL) were tested, proposing to obtain chromatographic peaks with the acceptable
analytical performance of the lipids (Table II).
The system’s suitability was tested by the tailing factor (T
f )and the number of theoretical
plates (N). The oven temperature was maintained at 45°C, and detection was performed
at 210 nm wavelength. The sample volumes of 10 µL were injected in each analysis. The
analysis was carried out for 20 minutes.
VALIDATION OF METHOD
The developed method was validated considering parameters of specificity, linearity,
accuracy, precision, the LOD, and the LOQ according to ICH Q2(R1).16,17
Specificity. The selectivity was investigated by injecting mobile phase (blank) solution,
phosphatidylcholine, Cer-NP, cholesterol samples, and liposome formulation, separately.
Then, the analysis was evaluated using a blank solution to identify the peak of Cer-NP and
other lipid components. Additionally, the lipid components in the liposomes were analyzed
as described in Section Analytical Equipment and Chromatographic Conditions. All samples were
performed in three replicates. The results of peak area and retention time were statistically
analyzed using a one-way analysis of variance (ANOVA) with a significance level of 0.05.
Linearity. The solutions consisting of Cer-NP were prepared at the range of liposome
formulation concentration from 80 µg/mL to 480 µg/mL, performing at least three
replicates. Then, the assays were analyzed to evaluate the linearity of Cer-NP. The data
were fitted using linear least squares regression. The correlation coefficient significance and
Table
II
The
Chromatographic
Conditions
of
Trials
Mobile
Phase
System,
Flow
Rate
and
Injection
Volume,
and
Results
the
Retention
Times,
Tailing
Factors,
and
the
Number
of
Theoretical
Plates
of
Cer-NP
Chromatograms
HPLC
conditions
Retention
time
(min)
Tailing factor
Number
of theoretical plates
Suitability
Mobile
phase
system (MeOH:ACN)
Flow
rate
Stationary phase
Injection volume
Phosphatidylcholine
Cer-NP
Cholesterol
Cer-NP
Cer-NP
Peak
quality
Trial
1
10:0
1
C18
100
5.7
6.3
8.3
1.162
320.7
Peak
depletion
Trial
2
9:1
1
C18
100
4.9
6.7
8.6
1.336
2569.6
Peak
depletion
Trial
3
8:2
1
C18
100
6.7
7.3
9.1
1.169
5969.9
Overlapping
Trial
4
7:3
1
C18
100
7.1
8.2
9.9
2.693
1257.1
Overlapping
Trial
5
6:4
1
C18
100
7.3
8.9
10.4
1.383
4759.4
Unqualified
Trial
6
9:1
0.8
C18
80
6.6
ND
8.4
ND
ND
Peak
depletion
Trial
7
9:1
0.8
C18
50
6.4
ND
8.2
ND
ND
Peak
depletion
Trial
8
9:1
0.8
C18
10
6.4
ND
8.1
ND
ND
Peak
depletion
Trial
9
9:1
0.5
C18
80
10.3
ND
13.2
ND
ND
Overlapping
Trial
10
9:1
0.5
C18
50
10.3
ND
13.1
ND
ND
Overlapping
Trial
11
9:1
0.5
C18
10
10.4
ND
13.2
ND
ND
Overlapping
Trial
12
6:4
0.8
C18
80
6.9
8.4
10.3
1.303
3594.0
Suitable
Trial
13
6:4
0.8
C18
50
6.6
8.1
9.9
ND
ND
Unqualified
Trial
14
6:4
0.8
C18
10
6.9
8.9
10.3
1.258
5983.8
Suitable
Trial
15
6:4
0.5
C18
80
10.5
13.1
15.9
ND
ND
Unqualified
Trial
16
6:4
0.5
C18
50
10.5
13.0
15.8
0.851
3792.8
Suitable
Trial
17
6:4
0.5
C18
10
10.7
13.5
15.8
1.194
5913.4
Suitable
Trial
17’
6:4
0.5
C8
10
11.6
ND
ND
1.067
ND
Peak
depletion
Note:
ND
=
Not
determined.
280 JOURNAL OF COSMETIC SCIENCE
Previous Page Next Page